Drug and medical device breakthroughs do not reach patients because they’re clever in a lab. They reach patients when innovation, regulatory strategy, partnerships, clinical evidence and commercial reality line up at the same time, and that’s where things get messy. We’re launching Lab to Lives with a simple goal: talk honestly about what slows life sciences down and what actually helps.
We start by introducing our new co-host dynamic and mapping where we each work across the life sciences “value streams” from early R&D to compliance and commercialization. With perspectives from diagnostics, medtech and pharma, we explore why devices and drugs now overlap, why manufacturing is often the blind spot, and why modern startups can look less like research labs and more like project management teams coordinating CROs across an ecosystem.
Then we go straight into one of the biggest debates in biotech and medtech: is regulation the barrier, or is it our approach to proving safety and efficacy? We unpack risk-benefit thinking, the power of precedent, and why innovators often choose the safest regulatory path even when a different approach could unlock better products. Along the way, we talk about culture clashes between startups and big pharma, incentives that shape decisions, and how to regain agency by building a clear evidence argument regulators can assess.
If you care about drug development, medical devices, regulatory affairs, FDA and EMA expectations, and the real mechanics of translating science into patient impact, come join the conversation. Subscribe, share this with someone building in life sciences, and leave a review with the barrier you think we should tackle next.
Podden och tillhörande omslagsbild på den här sidan tillhör
Ivanna Rosendal. Innehållet i podden är skapat av Ivanna Rosendal och inte av,
eller tillsammans med, Poddtoppen.
